Companies / Tcr2 Therapeutics Inc.
Tcr2 Therapeutics Inc.
TCRRCIK 1750019
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| May 4, 2023 | Tang Kevin 10% owner | Buy Open-market buy | Common Stock | $193.9K | +104K +2.64% | 4,049,041 | medium |
| May 5, 2023 | Tang Kevin 10% owner | Buy Open-market buy | Common Stock | $181.9K | +96K +2.37% | 4,144,800 | medium |
| May 5, 2023 | Tang Kevin 10% owner | Buy Open-market buy | Common Stock | $137.9K | +71K +1.71% | 4,215,864 | medium |
| May 22, 2023 | Mpm Asset Management LLC 10% owner | Sell Open-market sale | Common Stock | $131.9K | -70K -18.75% | 304,001 | medium |
| May 22, 2023 | Gadicke Ansbert Director | Sell Open-market sale | Common Stock | $131.9K | -70K -18.75% | 304,001 | medium |
| May 22, 2023 | Mpm Asset Management LLC 10% owner | Exercise In-the-money exercise | Common Stock | $131.9K | +178K +91.00% | 374,171 | low |
| May 22, 2023 | Gadicke Ansbert Director | Exercise In-the-money exercise | Common Stock | $131.9K | +178K +91.00% | 374,171 | low |
| Dec 9, 2021 | Menzel Garry E CEO | Exercise Option exercise | Common Stock | $129.5K | +175K +3882.85% | 179,507 | low |